Purixan (mercaptopurine oral suspension) / Nova Labs - LARVOL DELTA

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (clinicaltrials.gov) - P2/3 | N=1708 | Not yet recruiting | Sponsor: Children's Oncology Group

New P2/3 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov) - P2/3 | N=790 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Mar 2028 ➔ Sep 2028

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BCL2

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Combination therapy • Enrollment closed • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Suspended | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2029 ➔ Sep 2027 | Trial primary completion date: Jun 2029 ➔ Sep 2027

Combination therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2030 ➔ Jun 2029 | Trial primary completion date: Mar 2030 ➔ Jun 2029

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Recruiting

Combination therapy • Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Suspended | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2029 ➔ Mar 2030 | Trial primary completion date: Dec 2029 ➔ Mar 2030

Combination therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov) - P2/3 | N=793 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BCL2 • CEP72

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Suspended | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2029 ➔ Dec 2029 | Trial primary completion date: Sep 2029 ➔ Dec 2029

Combination therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Suspended | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Suspended

Trial suspension • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2028 ➔ Sep 2029 | Trial primary completion date: Mar 2028 ➔ Sep 2029

Combination therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

High-Dose MTX Does Not Reduce CNS Relapse in Pediatric ALL (Medscape) - "'As researchers in hematology, we look at it as our duty to question the standard approaches that we use to treat patients, even those that we thought of as tried-and-true,' said briefing moderator Mikkael Sekeres....This is one of the abstracts that 'challenge some of those standards and in fact reveal that in many cases, giving less therapy and being less restrictive is actually better for patients, or at least no worse.'"

Media quote

Acceptability of Multiparticulate Dosing Using Sympfiny Delivery System with Children (Age 1-12). (PubMed, Pharmaceutics) - "PURIXAN (mercaptopurine) and Methotrexate have been identified as potential chemotherapy drugs that could benefit from reformulation into multiparticulate. Over time, more children ages 1-4 did not open their mouths; consistently around 15-20% of 1-4 years olds spat the placebo. However, approximately 95% of parents found the Sympfiny system acceptable and indicated that they would use it to deliver medication to their child."

Journal • Pediatrics

AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=6720 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2027 ➔ Mar 2028 | Trial primary completion date: Dec 2027 ➔ Mar 2028

Combination therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Ozanimod (Zeposia) for ulcerative colitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - P3; N=6720; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2027 ➔ Dec 2027; Trial primary completion date: Jun 2027 ➔ Dec 2027

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov) - P2/3; N=1000; Recruiting; Sponsor: St. Jude Children's Research Hospital

Clinical • IO biomarker • New P2/3 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BCL2

Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. (PubMed, Cancer Chemother Pharmacol) - P4 | "Non-inferiority of liquid 6MP formulation compared with 6MP tablet was not demonstrated. Yet, maintenance therapy doses are adjusted by degree of myelosuppression and not by 6MP dose. Thus, in spite of a lower bioavailability, a liquid 6MP formulation is still desirable in a clinical setting, especially for children. However, if shifting between 6MP formulation is indicated, dose adjustments should be anticipated to maintain equivalent treatment intensity in children with ALL. The study is registered on clinicaltrials.gov (NCT01906671). Date of registration: 24.07.13."

Clinical • Journal • PK/PD data • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults (clinicaltrials.gov) - P1; N=19; Completed; Sponsor: Massachusetts General Hospital; Active, not recruiting ➔ Completed; Trial completion date: Jul 2021 ➔ Nov 2019

Clinical • Trial completion • Trial completion date

IS 6-MERCAPTOPURINE SUSPENSION THERAPEUTICALLY EQUIVALENT TO TABLET IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA DURING MAINTENANCE THERAPY? (SIOP 2019) - "Background/Objectives: Xaluprine®, a 6-mercaptopurine (6-MP) suspension, has obtained its market authorization in 2012. This study highlighted that therapeutic drug monitoring after a 6-MP formulation change is essential to optimize the individual 6-MP dose."

Clinical

Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma (clinicaltrials.gov) - P3; N=6720; Recruiting; Sponsor: National Cancer Institute (NCI); Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults (clinicaltrials.gov) - P1; N=19; Active, not recruiting; Sponsor: Massachusetts General Hospital; Recruiting ➔ Active, not recruiting

Enrollment closed

Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma (clinicaltrials.gov) - P3; N=6720; Not yet recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • Combination therapy • New P3 trial